Die Zukunft der Stammzellenforschung
-
Erwin-Schrödinger-Saal
Plenary
/
German and English language
| |||||
| |||||
|
FRS, D.Sc. Martin EVANS
Nobel Laureate in Medicine; Director of the School of Biosciences and Professor of Mammalian Genetics, Cardiff School of Biosciences, Cardiff University
| Gained his BA in Biochemistry from Christ College, University of Cambridge in 1963. He received an MA in 1966 and a D.Sc. in 1996. In 1969 he was awarded a Ph.D. degree from University College, London. | |
| After graduating from Cambridge, he decided on a career studying the genetic control of vertebrate development. His early Ph.D. research led him to explore the use of cultures of mouse teratocarcinoma stem cells in tissue culture systems. He was the first to maintain these cells in tissue culture under conditions where their ability to differentiate was retained indefinitely. | |
| It was not until 1981, after his return to Cambridge, that he was able to isolate similar cells from normal mouse embryos. Subsequently he and his colleagues demonstrated that these cells which became known as "Embryonic Stem Cells" (ES cells) were able to be used to fully regenerate fertile breeding mice from the tissue culture cells and that these could therefore carry mutations introduced and selected or screened for in culture. This is now the basis of all mouse knockout and targeted genetic manipulation. | |
| These fundamental developments created new routes to experimental mammalian genetics and hence functional genomics. Since then, Sir Martin, who came to Cardiff University s School of Biosciences in 1999, has been exploiting gene knockout and gene trap methods both for novel discovery and to create animal modes of human disease. From his laboratory came the first demonstration of gene therapy to cure the deficit in Cystic Fibrosis in a whole animal and recently, from a mutated mouse model, insights into the breast cancer gene BRCA2 function. | |
| Sir Martin has published more than 120 scientific papers. He was elected a Fellow of the Royal Society in 1993 and is a founder Fellow of the Academy of Medical Sciences. In 1993 he was awarded the Walter Cottman Fellowship and the William Bate Hardy Prizes. He was awarded the prestigious Albert Lasker Award for Basic Medical Research in the US in 2001. In 2002 he was awarded an honorary doctorate from Mount Sinai School of Medicine in New York, regarded as one of the world's foremost centres for medical and scientific training. | |
| Sir Martin is also a member of the Wales Gene Park - which has brought together genetics, life sciences and clinical expertise from across Wales to create a new centre for research of national and international importance which offers state-of-the-art facilities for research, education and commercial exploitation. | |
| He was knighted in 2004 for his services to medical science and in 2009 was awarded the Gold Medal of The Royal Society of Medicine in recognition of his valuable contribution to medicine. |
Dr. Hans SCHÖLER
Geschäftsführender Direktor und Leiter der Abteilung Zell- und Entwicklungsbiologie, Max-Planck-Institut für molekulare Biomedizin, Münster
| 1982 | Diplom Biologie, Universität Heidelberg |
| 1984-1986 | Wissenschaftlicher Mitarbeiter, Zentrum für Molekulare Biologie Heidelberg (ZMBH) Universität Heidelberg |
| 1985 | Ph.D. Molekularbiologie, Zentrum für Molekulare Biologie (ZMBE) der Universität Heidelberg |
| 1986-1988 | Forschungsgruppenleiter, Boehringer Mannheim, Forschungszentrum Tutzing |
| 1988-1991 | Wissenschaftlicher Mitarbeiter, Max-Planck-Institut für Biophysikalische Chemie, Göttingen |
| 1991-1999 | Leiter einer Forschungsgruppe am Europäischen Laboratorium für Molekularbiologie (EMBL), Heidelberg |
| 1994 | Habilitation, Ruprecht-Karls-Universität Heidelberg (Venia Legendi in Molekularbiologie) |
| 1999-2004 | Professor für Reproduktionsphysiologie an der "School of Veterinary Medicine" und Direktor des "Center of Animal Transgenesis and Germ Cell Research" an der University of Pennsylvania, USA |
| 2000-2004 | Inhaber des "Marion Dilley and David George Jones" Lehrstuhls für Reproduktionsmedizin |
| seit 2004 | Außerordentlicher Professor für Biochemie, University of Pennsylvania, School of Veterinary Medicine, Philadelphia, USA |
| Vollmitglied der Medizinischen Fakultät der Westfälischen Wilhelms-Universität Münster | |
| Direktor der Abteilung Zell- und Entwicklungsbiologie, Max-Planck-Institut für molekulare Biomedizin, Münster | |
| seit 2009 | Außerordentlicher Professor der Medizinischen Hochschule Hannover (MHH) |
Mag. Dr. Markus HENGSTSCHLÄGER
Head, Institute of Medical Genetics; Director, Centre of Pathobiochemistry and Genetics, Medical University of Vienna
| 1986-1990 | Studium Genetik, Diplomarbeit am Children Cancer Research Institute St. Anna Kinderspital, Sponsion zum Magister der Genetik (Auszeichnung, Studienverkürzung) |
| 1990-1992 | Dissertation als Universitätsassistent am Vienna Biocenter, Promotion zum Doktor der Genetik (Auszeichnung) |
| 1993-1994 | Postdoc an der Yale University, USA |
| 1995 | Universitätsassistent Universität Wien |
| 1997 | Habilitation |
| 1998 | außerordentlicher Universitätsprofessor |
| 2004 | Ausbildungsabschluss: Fachhumangenetiker |
| Berufung (internationales Berufungsverfahren) zum Universitätsprofessor für Medizinische Genetik an der Medizinischen Universität Wien | |
| seit 2004 | Moderator der Medizin- und Wissenschaftssendung "Radiodoktor", ORF, Ö1 Radio |
| seit 2005 | Leiter der Abteilung Genetik, Institut für Kinderwunsch, Lainzerstraße, Wien |
| 2005-2009 | Leiter der Abteilung für Medizinische Genetik, Universitätsklinik für Frauenheilkunde, Medizinische Universität Wien |
| seit 2009 | Vorstand des Instituts für Medizinische Genetik, Medizinische Universität Wien |
| seit 2011 | zusätzlich Organisationseinheitsleiter des Zentrum für Pathobiochemie und Genetik der Medizinischen Universität Wien |
| - Wissenschaftliche Arbeitsgebiete: Erforschung der humangenetischen Erkrankung Tuberöse Sklerose; Stammzellen aus dem humanen Fruchtwasser; Deregulation von Zelldifferenzierungsprozessen bei humangenetischen Erkrankungen; pränatale und postnatale genetische Routinediagnostik; Genetik in der Reproduktionsmedizin; Bioethik (Schwerpunkt medizinische Genetik und Stammzellforschung). | |
| - Alleinverantwortliche Verfassung und Leitung der Durchführung einer Vielzahl von Drittmittel-Projekten gefördert durch z.B. Fonds zur Förderung der wissenschaftlichen Forschung (FWF), Marie Curie Research Network (Forschungsförderung der Europäischen Union), Oesterreichische Nationalbank, Bundesministerium für Wissenschaft und Verkehr, Herzfeldersche Familienstiftung, Komission Onkologie der | |
| Wiener Medizinischen Fakultät, Anton-Dreher-Gedächtnisstiftung, Hochschuljubiläumsstiftung der Stadt Wien. |
